UPDATE: Piper Sandler Starts Aeglea Biotherapeutics (AGLE) at Overweight
Tweet
Share
E-mail
Get Alerts AGLE Hot Sheet
Price: $12.01 --0%
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
(Updated - May 4, 2020 6:06 AM EDT)
(updating analyst name)
Piper Sandler analyst Edward Tenthoff initiates coverage on Aeglea Biotherapeutics (NASDAQ: AGLE) with a Overweight rating.
For an analyst ratings summary and ratings history on Aeglea Biotherapeutics click here. For more ratings news on Aeglea Biotherapeutics click here.
Shares of Aeglea Biotherapeutics closed at $7.50 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
- JPMorgan Resumes SanDisk (SNDK) at Overweight
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
